Fig. 1: Characteristics of CAR-T cells. | Blood Cancer Journal

Fig. 1: Characteristics of CAR-T cells.

From: Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial

Fig. 1

A The anti-CD19/20 CAR was constructed via integrating the CD20 single-chain variable fragment (scFv) from Leu16 and CD19 scFv from FMC63 monoclonal antibody, along with the hinge and transmembrane domains of CD8 and the cytoplasmic domains of 4-1BB and CD3 zeta signaling ___domain. CD20 derived from Leu16 and CD19 derived from FMC63 monoclonal antibody. B Percentage-specific cleavage of CAR-T cells to target tumor cells determined by an 18-h culture LDH assay at indicated E: T ratio. C Cytokine concentrations secreted by classified anti-19 or anti-20 or anti-19&20 CAR-T cells in response to K562 tumor cells expressing K562-CD19 or K562-CD20 or K562-CD19&CD20. Specific cytokine production was determined by enzyme-linked immunosorbent assay (ELISA) (n = 3 donors). Three independent experiments were performed, and representative results are shown. NT nontransduced, TNF-a tumor necrosis factor-a, IFN-γ interferon-γ, IL-2 Interleukin-2.

Back to article page